Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 140.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 140.
GASTROGRAFIN vs OMNIPAQUE 140
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent